Komori
Earnings190AChordia Therapeutics Inc.Pharmaceuticals

Financial Results for the Fiscal Year Ended August 2026 [Japanese GAAP] (Non-consolidated)

For the fiscal year ended August 2026, the Company had no business revenue and posted operating, ordinary and net losses, but the loss narrowed from the previous fiscal year due to lower research and development expenses and other factors. The earnings forecast for the fiscal year ending August 2027 has not been disclosed because it is difficult to make a reasonable calculation.

Worth reading
61In focus
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
316
¥ million
Wording
Conditional
How definitive the wording is.

Results for this period

Full year1 September 2025 to 31 August 2026Non-consolidated (standalone)Japanese GAAP
Operating profit-1,473¥ million
Ordinary income-1,450¥ million
Net income attributable to owners of the parent-1,455¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share¥(19.74)
Financial position at period-end
Total assets2,114¥ million
of which net assets 1,925 ¥ millionEquity ratio 90.7%vs. prior year-end -0.1pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-1,418
Investment-2
Financials+924
Net change-496

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥2,052 million
Outlook and shareholder returns
Full-year earnings forecast
Net SalesNot disclosed
Operating profitNot disclosed
Ordinary incomeNot disclosed
Net incomeNot disclosed
ReasonNot disclosed because a reasonable earnings forecast cannot be calculated at this time.
Annual Dividend Forecast¥0.00 → ¥0.00
Factors Behind Changes in Business Performance

There was no business revenue. Research and development expenses were ¥1,154 million, down 19.0% from the previous fiscal year, and selling, general and administrative expenses were ¥318 million, down 12.5%.

Disclosure regarding the going concern assumption

Although events or conditions exist that raise significant doubt about the going concern assumption, the Company recognizes that there is no material uncertainty regarding going concern. There are no applicable matters to disclose in the notes regarding going concern.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsPayment for the issuance of the 12th Stock Acquisition Rights through a third-party allotment was completed on 9 September 2026. Partial exercise between 11 September and 30 September 2026 resulted in the issuance of 100,000 common shares.
Impairment loss¥2,596 thousand
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥2,596 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End77,258,400 shares
Treasury Shares at Period-End0 shares
Results for this period
ItemDetails
Fiscal Period ClassificationFull year
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 September 2025 to 31 August 2026
Operating profit¥-1,473 million
Ordinary income¥-1,450 million
Profit attributable to owners of the parent¥-1,455 million
Net income per share¥(19.74)
Equity ratioEnd of the current fiscal period 90.7% / End of previous period 90.8%
Total assets¥2,114 million
Net assets¥1,925 million
Cash flows from operating activities¥-1,418 million
Cash flows from investing activities¥-2 million
Cash flows from financing activities¥924 million
Cash and cash equivalents at end of period¥2,052 million
Full-year earnings forecastNet Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Not disclosed because a reasonable earnings forecast cannot be calculated at this time.
Annual Dividend Forecast¥0.00 → ¥0.00
Impairment loss¥2,596 thousand
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥2,596 thousand
Disclosure regarding the going concern assumptionAlthough events or conditions exist that raise significant doubt about the going concern assumption, the Company recognizes that there is no material uncertainty regarding going concern. There are no applicable matters to disclose in the notes regarding going concern.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Material subsequent eventsPayment for the issuance of the 12th Stock Acquisition Rights through a third-party allotment was completed on 9 September 2026. Partial exercise between 11 September and 30 September 2026 resulted in the issuance of 100,000 common shares.
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End77,258,400 shares
Treasury Shares at Period-End0 shares
Factors Behind Changes in Business PerformanceThere was no business revenue. Research and development expenses were ¥1,154 million, down 19.0% from the previous fiscal year, and selling, general and administrative expenses were ¥318 million, down 12.5%.
Items this document does not state (11)
Net SalesOperating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationChanges in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Research and development expenses decreased 19.0% from the previous fiscal year, while selling, general and administrative expenses also decreased 12.5%, narrowing the operating loss from ¥1,789 million to ¥1,473 million.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results for the Fiscal Year Ended August 2026 [Japanese GAAP] (Non-consolidated) | Chordia Therapeutics Inc. (190A) timely disclosure | Komori